Owkin Pricing & Plans 2026

Name: Owkin
Brand: Owkin
Availability: InStock

Complete pricing guide for Owkin. Compare all plans, analyze costs, and find the perfect tier for your needs.

Not sure if free is enough? See our Free vs Paid comparison →
Still deciding? Read our full verdict on whether Owkin is worth it →

💎3 Paid Plans

⚡No Setup Fees

Choose Your Plan

Enterprise Partnership

Contact Sales

✓Custom enterprise contract with negotiated scope and terms
✓Access to MOSAIC federated learning platform across 15+ academic medical centers
✓Computational pathology and biomarker discovery capabilities
✓K Pro AI Scientist for pharma decision-making
✓Spatial and multi-omics reporting
✓Dedicated support and onboarding

Contact Sales →

Diagnostic Licensing

Contact Sales

✓MSIntuit CRC FDA-cleared diagnostic deployment
✓Integration with existing pathology workflows
✓Volume-based licensing terms
✓Clinical support and regulatory documentation

Start Free Trial →

Research Collaboration

Contact Sales

✓Academic and institutional research partnerships
✓Access to federated learning network for specific studies
✓Co-publication and data sharing agreements
✓Tailored scope for academic medical centers

Start Free Trial →

Pricing sourced from Owkin · Last verified March 2026

Feature Comparison

Features	Enterprise Partnership	Diagnostic Licensing	Research Collaboration
Custom enterprise contract with negotiated scope and terms	✓	✓	✓
Access to MOSAIC federated learning platform across 15+ academic medical centers	✓	✓	✓
Computational pathology and biomarker discovery capabilities	✓	✓	✓
K Pro AI Scientist for pharma decision-making	✓	✓	✓
Spatial and multi-omics reporting	✓	✓	✓
Dedicated support and onboarding	✓	✓	✓
MSIntuit CRC FDA-cleared diagnostic deployment	—	✓	✓
Integration with existing pathology workflows	—	✓	✓
Volume-based licensing terms	—	✓	✓
Clinical support and regulatory documentation	—	✓	✓
Academic and institutional research partnerships	—	—	✓
Access to federated learning network for specific studies	—	—	✓
Co-publication and data sharing agreements	—	—	✓
Tailored scope for academic medical centers	—	—	✓

Is Owkin Worth It?

✅ Why Choose Owkin

• Unique federated learning architecture via MOSAIC enables training on real-world hospital data without centralizing patient records, providing access to more diverse and representative datasets than competitors
• FDA 510(k)-cleared MSIntuit CRC diagnostic demonstrates regulatory validation, with the ability to triage approximately 30% of colorectal cancer cases without confirmatory molecular testing
• Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration validate platform value for top-tier pharmaceutical companies
• Over 80 peer-reviewed publications in journals like Nature Medicine and The Lancet Digital Health provide strong scientific credibility compared to many AI biotech peers
• Founded in 2016 with over $300M raised and global presence across 7 offices (Paris, London, New York, Cambridge MA, Geneva, Nantes), giving institutional clients confidence in long-term viability
• Multimodal approach combining pathology, genomics, spatial-omics and clinical data captures biological complexity beyond single-modality platforms

⚠️ Consider This

• Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
• Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
• Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
• No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
• Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging

What Users Say About Owkin

👍 What Users Love

✓Unique federated learning architecture via MOSAIC enables training on real-world hospital data without centralizing patient records, providing access to more diverse and representative datasets than competitors
✓FDA 510(k)-cleared MSIntuit CRC diagnostic demonstrates regulatory validation, with the ability to triage approximately 30% of colorectal cancer cases without confirmatory molecular testing
✓Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration validate platform value for top-tier pharmaceutical companies
✓Over 80 peer-reviewed publications in journals like Nature Medicine and The Lancet Digital Health provide strong scientific credibility compared to many AI biotech peers
✓Founded in 2016 with over $300M raised and global presence across 7 offices (Paris, London, New York, Cambridge MA, Geneva, Nantes), giving institutional clients confidence in long-term viability
✓Multimodal approach combining pathology, genomics, spatial-omics and clinical data captures biological complexity beyond single-modality platforms

👎 Common Concerns

⚠Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
⚠Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
⚠Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
⚠No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
⚠Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging
⚠Regulatory approval for AI diagnostics varies by jurisdiction, and expanding beyond FDA-cleared products to additional cancer types and international markets involves lengthy timelines

Pricing FAQ

How much does Owkin cost?

Owkin offers multiple pricing tiers to suit different needs and budgets. Pricing varies based on features, usage limits, and support level. Check the current pricing page for the most up-to-date costs and features.

Does Owkin offer a free trial?

Owkin typically offers a free trial period for new users to test the platform. Contact their sales team or check their website for current trial offers and duration.

What's included in each Owkin pricing plan?

Each Owkin pricing plan includes different feature sets, usage limits, and support levels. Higher-tier plans typically offer more advanced features, higher usage quotas, priority support, and additional integrations. Review the detailed comparison on their pricing page.

Can I change my Owkin plan later?

Most SaaS tools including Owkin allow you to upgrade or downgrade your plan as your needs change. Some changes take effect immediately, while others might apply at your next billing cycle. Check their billing settings or contact support for specific policies.

Ready to Get Started?

AI builders and operators use Owkin to streamline their workflow.

Try Owkin Now →

More about Owkin

Review Alternatives Free vs Paid Pros & Cons Worth It?Tutorial

Choose Your Plan

Enterprise Partnership

Contact Sales

✓Custom enterprise contract with negotiated scope and terms
✓Access to MOSAIC federated learning platform across 15+ academic medical centers
✓Computational pathology and biomarker discovery capabilities
✓K Pro AI Scientist for pharma decision-making
✓Spatial and multi-omics reporting
✓Dedicated support and onboarding

Contact Sales →

Diagnostic Licensing

Contact Sales

✓MSIntuit CRC FDA-cleared diagnostic deployment
✓Integration with existing pathology workflows
✓Volume-based licensing terms
✓Clinical support and regulatory documentation

Start Free Trial →

Research Collaboration

Contact Sales

✓Academic and institutional research partnerships
✓Access to federated learning network for specific studies
✓Co-publication and data sharing agreements
✓Tailored scope for academic medical centers

Start Free Trial →

Pricing sourced from Owkin · Last verified March 2026

Feature Comparison

Features	Enterprise Partnership	Diagnostic Licensing	Research Collaboration
Custom enterprise contract with negotiated scope and terms	✓	✓	✓
Access to MOSAIC federated learning platform across 15+ academic medical centers	✓	✓	✓
Computational pathology and biomarker discovery capabilities	✓	✓	✓
K Pro AI Scientist for pharma decision-making	✓	✓	✓
Spatial and multi-omics reporting	✓	✓	✓
Dedicated support and onboarding	✓	✓	✓
MSIntuit CRC FDA-cleared diagnostic deployment	—	✓	✓
Integration with existing pathology workflows	—	✓	✓
Volume-based licensing terms	—	✓	✓
Clinical support and regulatory documentation	—	✓	✓
Academic and institutional research partnerships	—	—	✓
Access to federated learning network for specific studies	—	—	✓
Co-publication and data sharing agreements	—	—	✓
Tailored scope for academic medical centers	—	—	✓

Is Owkin Worth It?

✅ Why Choose Owkin

• Unique federated learning architecture via MOSAIC enables training on real-world hospital data without centralizing patient records, providing access to more diverse and representative datasets than competitors
• FDA 510(k)-cleared MSIntuit CRC diagnostic demonstrates regulatory validation, with the ability to triage approximately 30% of colorectal cancer cases without confirmatory molecular testing
• Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration validate platform value for top-tier pharmaceutical companies
• Over 80 peer-reviewed publications in journals like Nature Medicine and The Lancet Digital Health provide strong scientific credibility compared to many AI biotech peers
• Founded in 2016 with over $300M raised and global presence across 7 offices (Paris, London, New York, Cambridge MA, Geneva, Nantes), giving institutional clients confidence in long-term viability
• Multimodal approach combining pathology, genomics, spatial-omics and clinical data captures biological complexity beyond single-modality platforms

⚠️ Consider This

• Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
• Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
• Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
• No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
• Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging

What Users Say About Owkin

👍 What Users Love

✓Unique federated learning architecture via MOSAIC enables training on real-world hospital data without centralizing patient records, providing access to more diverse and representative datasets than competitors
✓FDA 510(k)-cleared MSIntuit CRC diagnostic demonstrates regulatory validation, with the ability to triage approximately 30% of colorectal cancer cases without confirmatory molecular testing
✓Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration validate platform value for top-tier pharmaceutical companies
✓Over 80 peer-reviewed publications in journals like Nature Medicine and The Lancet Digital Health provide strong scientific credibility compared to many AI biotech peers
✓Founded in 2016 with over $300M raised and global presence across 7 offices (Paris, London, New York, Cambridge MA, Geneva, Nantes), giving institutional clients confidence in long-term viability
✓Multimodal approach combining pathology, genomics, spatial-omics and clinical data captures biological complexity beyond single-modality platforms

👎 Common Concerns

⚠Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
⚠Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
⚠Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
⚠No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
⚠Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging
⚠Regulatory approval for AI diagnostics varies by jurisdiction, and expanding beyond FDA-cleared products to additional cancer types and international markets involves lengthy timelines

Pricing FAQ

How much does Owkin cost?

Does Owkin offer a free trial?

Owkin typically offers a free trial period for new users to test the platform. Contact their sales team or check their website for current trial offers and duration.